RLAY Maintained by HC Wainwright & Co. -- Price Target Raised to $29
HC Wainwright & Co. has maintained a "Buy" rating for Relay Therapeutics (RLAY) and raised its price target to $29, reflecting cautious optimism despite the company's financial challenges. However, GuruFocus's GF Value™ indicates RLAY is significantly overvalued by 493.4%, and its GF Score™ of 42/100 points to major weaknesses in profitability and valuation. Insider selling activity also suggests a lack of confidence from company insiders.
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says
HC Wainwright has increased its price target for Relay Therapeutics (NASDAQ:RLAY) to $29 from $28, maintaining a "buy" rating and projecting a 39.8% upside. Despite a recent quarterly loss of $0.41 per share and revenue below estimates, analyst sentiment remains largely positive, with a consensus "Moderate Buy" rating and an average target price of $25.92. Insider selling by CEO Sanjiv Patel and Peter Rahmer was also noted, alongside significant institutional investment in the company.
Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE
Bank of America Corp DE significantly increased its stake in Relay Therapeutics (NASDAQ:RLAY) by 86.1% during the first quarter, now owning 1.01% of the company's stock valued at $19.28 million. Other institutional investors and hedge funds also made substantial changes to their positions, with 96.98% of the company's stock owned by institutional investors. Insiders have sold a considerable amount of shares recently, while analysts maintain a "Moderate Buy" rating with a consensus target price of $25.83.
Relay Therapeutics (RLAY) Reported Q2 Results, Is The Premium P B Multiple Justified?
Relay Therapeutics (RLAY) reported Q2 2026 results with revenue of US$0.35 million and a net loss of US$83.71 million. Despite recent share price recovery, the company's P/B ratio of 5.1x is higher than its peers and the broader biotech industry, suggesting it is overvalued. Investors are advised to consider the ongoing net losses and reliance on clinical trial progress as key risks.
Relay Therapeutics (RLAY) Stock May Be Fully Valued After A 7x Run
Relay Therapeutics (RLAY) stock has seen a significant 7x return over the past year but appears overvalued based on broad valuation checks. The company passes only one of six valuation metrics and trades at a P/B ratio of 5.1x, higher than the biotech industry average of 2.5x. While future drug development potential could justify the price, the current valuation relies heavily on the company's pipeline and execution given its current loss-making status.
Timothy G. Youngquist 2020 Irrevocable Trust Boosts Stake in Relay Therapeutics, Inc. $RLAY
The Timothy G. Youngquist 2020 Irrevocable Trust significantly increased its stake in Relay Therapeutics, Inc. (RLAY) by 60.6% in the second quarter, now owning 801,464 shares valued at approximately $15 million. This move comes despite recent insider selling by executives and the company missing quarterly EPS and revenue estimates. Analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $25.83.
Handelsbanken Fonder AB Buys New Shares in Relay Therapeutics, Inc. $RLAY
Handelsbanken Fonder AB recently purchased 59,100 shares of Relay Therapeutics (NASDAQ:RLAY) valued at $1.1 million, while other institutional investors also adjusted their holdings. Insiders at Relay Therapeutics have sold a significant number of shares, totaling $7.23 million over the last 90 days. Despite the insider selling and missed quarterly earnings expectations, analysts maintain a "Moderate Buy" consensus rating for the company with an average price target of $25.83.
Relay Therapeutics Insider Sold Shares Worth $979,886, According to a Recent SEC Filing
An insider at Relay Therapeutics (RLAY) sold shares valued at $979,886, as reported in a recent SEC filing. This transaction occurred on August 18, 2026, and is one of several insider share sales reported around the same date. Relay Therapeutics is a clinical-stage biotechnology company focused on developing therapies for cancer and genetic diseases.
Relay Therapeutics (RLAY) CFO sells shares via preset trading plan
Relay Therapeutics (RLAY) Chief Financial Officer, Thomas Catinazzo, sold 17,717 shares of common stock on August 14, 2026, at a weighted average price of $19.74 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on October 30, 2025. Following the sale, Catinazzo directly holds 140,568 shares of Relay Therapeutics common stock, which includes restricted stock units.
Relay Therapeutics (RLAY) CEO sells 48K shares in plan trade
Relay Therapeutics (RLAY) President and CEO Sanjiv Patel sold 48,199 shares of common stock on August 17, 2026, at a weighted average price of $20.33 per share. This transaction was conducted under a Rule 10b5-1 trading plan adopted in October 2025. Following the sale, Patel directly holds 567,699 shares, with additional shares held indirectly in family trusts for which he disclaims beneficial ownership.
Relay Therapeutics stock hits 52-week high at 20.83 USD
Relay Therapeutics stock reached a 52-week high of $20.83, currently trading at $20.87 with a market capitalization of $4.52 billion and a 1-year return of 496%. Despite trading above its Fair Value according to InvestingPro, the surge reflects investor confidence. Several analysts have raised price targets and reiterated Buy ratings, citing progress in breast cancer treatment development, particularly for its lead asset zovegalisib.
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
The Zacks Analyst Blog highlights four AI-powered drug discovery stocks: Recursion Pharmaceuticals (RXRX), Schrödinger (SDGR), Relay Therapeutics (RLAY), and Absci (ABSI). These companies leverage AI and computational platforms to accelerate drug discovery, reduce costs, and improve success rates in pharmaceutical research. Each company has unique approaches, proprietary technologies, and advancing clinical pipelines, offering investors exposure to the transformative potential of AI in drug development.
Persistent Asset Partners Ltd Makes New $1.32 Million Investment in Relay Therapeutics, Inc. $RLAY
Persistent Asset Partners Ltd invested $1.32 million in Relay Therapeutics, acquiring 70,693 shares during Q2. This comes as Relay Therapeutics reported a quarterly loss and revenue miss, while company insiders sold approximately $7.23 million in stock over the past 90 days. Despite mixed analyst sentiment, the stock holds a consensus "Moderate Buy" rating with an average target price of $25.83.
Relay Therapeutics (NASDAQ:RLAY) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen has downgraded Relay Therapeutics (NASDAQ:RLAY) from a "Hold" to a "Sell" rating, despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $25.83. This downgrade follows the company's recent quarterly earnings report, where it missed both EPS and revenue estimates. Additionally, insider selling amounting to $7.23 million over the past 90 days was noted, while institutional investors hold a significant 96.98% stake.
PERCEPTIVE ADVISORS LLC Expands Relay Therapeutics Inc (RLAY) Stake -- Shares Look 421% Overvalued on GF Value
Perceptive Advisors LLC significantly increased its stake in Relay Therapeutics Inc (RLAY) by purchasing 13.67 million shares, bringing their total ownership to 6.40%. Despite this strong conviction from a specialized healthcare investment firm, GuruFocus identifies RLAY shares as "Significantly Overvalued" by 421% based on its GF Value, raising concerns for value investors even with the company's strong balance sheet and growth potential. The article highlights the discrepancy between market sentiment and intrinsic value, urging caution despite favorable short-term technical indicators.
Relay Therapeutics (RLAY): Commodore Capital group discloses 12M-share, 5.5% position
Commodore Capital LP and its affiliates, including Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz, have disclosed a beneficial ownership of 12,000,000 shares of Relay Therapeutics, Inc. (RLAY) common stock. This stake represents 5.5% of the outstanding common stock, based on 218,531,200 shares as of June 30, 2026. The group reports shared voting and shared dispositive power over these shares, with Commodore Capital LP acting as investment manager and Atkinson and Kramarz exercising investment discretion.
Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year
Relay Therapeutics (RLAY), a clinical-stage precision medicines company in targeted oncology with a $4.4 billion market cap, has seen its stock surge by 486% over the past year, trading near a new 3-year high. While technical momentum is strong with a 100% "Buy" opinion from Barchart and a Trend Seeker "Buy" signal, the company's fundamentals indicate an expected revenue decrease of over 30% this year, though it is projected to rise by 60.64% next year. Analysts are largely positive on the stock's future, despite its highly speculative nature, with price targets ranging from $20 to $32.
Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year
Relay Therapeutics (RLAY), a clinical-stage precision medicines company, has seen its stock surge by nearly 500% over the past year, trading near a new 3-year high. While technical momentum is strong, with a "Buy" signal from Barchart's Trend Seeker, the company's fundamentals indicate a projected revenue decrease of over 30% this year, though it is expected to rise significantly next year. Analysts are largely bullish on the stock, despite its speculative nature, due to its focus on collaboration and licensing revenue in targeted oncology.
Relay Therapeutics, Inc. $RLAY Shares Bought by California State Teachers Retirement System
California State Teachers Retirement System increased its stake in Relay Therapeutics (NASDAQ:RLAY) by 47.9% in the first quarter, now owning 174,099 shares valued at $1.73 million. Despite institutional ownership of nearly 97%, the company missed analyst expectations on its last quarterly earnings and revenue. Insiders have also sold a significant amount of shares recently, totaling $7.23 million over 90 days.
These Analysts Think Relay Therapeutics, Inc.'s (NASDAQ:RLAY) Sales Are Under Threat
Analysts have downgraded their revenue forecasts for Relay Therapeutics, Inc. (NASDAQ:RLAY) for 2026, cutting estimates from US$12m to US$11m and increasing expected losses per share to US$1.60. Despite the lowered revenue projections and increased anticipated losses, the consensus price target remains largely unchanged at US$26.77. The company's revenue growth is expected to improve compared to its past performance but still trails the industry average.
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Relay Therapeutics (NASDAQ:RLAY) recently released its second-quarter results, showing revenue significantly below analyst expectations and larger-than-modelled losses. As a result, analysts have cut 2026 revenue estimates and increased loss per share forecasts. Despite the weaker earnings outlook, the average price target remained unchanged, suggesting analysts do not anticipate a long-term impact on valuation, though the company's revenue decline is expected to be worse than industry peers.
These Analysts Think Relay Therapeutics, Inc.'s (NASDAQ:RLAY) Sales Are Under Threat
Analysts have downgraded their revenue forecasts for Relay Therapeutics (RLAY) for 2026, cutting estimates from US$12m to US$11m and expecting increased losses per share to US$1.60. Despite the lowered outlook, the consensus price target remains unchanged at US$26.77, suggesting that the weaker earnings are not anticipated to impact long-term valuation. The company is projected to grow faster in the future than in the past, though still slower than the broader industry.
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Relay Therapeutics, Inc. (NASDAQ:RLAY) recently released its second-quarter results, showing revenue of US$350k, 56% less than analysts expected, and losses of US$0.41 per share, which were larger than modeled. Following these results, analysts have cut their 2026 revenue estimates to US$10.2m and increased their loss per share forecasts to US$1.59. Despite the downgraded outlook, the average price target remained largely unchanged at US$26.77, suggesting analysts don't foresee a long-term impact on valuation, though the company is expected to underperform the industry in revenue growth.
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Following its Q2 earnings release, Relay Therapeutics, Inc. (NASDAQ:RLAY) experienced significant cuts to analyst revenue estimates for 2026 and increased loss-per-share forecasts. Despite this, the average price target remained stable at US$26.77, suggesting that the weaker short-term outlook might not impact the long-term valuation. The company's shrinking revenues are expected to moderate by 2026, though still underperforming the broader industry.
Relay Therapeutics (RLAY): Perceptive Advisors discloses 6.4% ownership stake
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have disclosed a beneficial ownership of 6.4% in Relay Therapeutics, Inc. This stake, totaling 14,106,187 shares, is held directly by the Master Fund. All reporting persons share voting and dispositive power over these shares, based on Relay Therapeutics having 219,141,631 shares outstanding as of July 31, 2026.
Relay Therapeutics, Inc. (NASDAQ:RLAY) Just Reported And Analysts Have Been Cutting Their Estimates
The user provided an incomplete article content ("Document") and thus a meaningful summary cannot be generated. Similarly, the cleaned content cannot be provided as the full article text is missing.
Citizens raises Relay Therapeutics stock price target on progress
Citizens has increased its price target for Relay Therapeutics (NASDAQ:RLAY) shares to $26.00 from $21.00, maintaining a Market Outperform rating, based on significant progress in breast cancer treatment development. The company's stock has shown strong performance, surging 514% over the past year, and its drug zovega is viewed as having potential as a backbone treatment in breast cancer and showing promising results in vascular malformations. Despite strong momentum, InvestingPro analysis suggests the shares may be overvalued, though the company boasts a strong balance sheet.
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Brokerages
Relay Therapeutics, Inc. (NASDAQ:RLAY) has received a "Moderate Buy" consensus rating from 14 analysts, with an average 12-month price target of $25.17, exceeding its current share price of $19.77. Despite recent positive analyst actions like price target increases, the company missed its latest quarterly earnings and revenue estimates. Additionally, company insiders have sold a significant number of shares totaling approximately $7.46 million over the past 90 days.
2 Things Relay Therapeutics (RLAY) Results Say About Its 4.9x P B Valuation
Relay Therapeutics reported a wider net loss and lower revenue in Q2 2026, leading to a slight pullback in its shares recently, though the stock has seen significant year-to-date gains. The company's P/B ratio of 4.9x is below its peers but still considered expensive compared to the broader US biotechs industry, reflecting market optimism for its future growth despite ongoing losses and funding risks. Investors are advised to consider the potential rewards and risks, including clinical and regulatory uncertainty, before making investment decisions.
Relay Therapeutics (NASDAQ:RLAY) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS
Relay Therapeutics (NASDAQ:RLAY) reported a quarterly loss of $0.41 per share, missing analysts' estimates by $0.02, with revenue of $0.35 million falling short of the $0.96 million consensus. Despite missing estimates, shares rose to $19.77, near its 52-week high, and analysts maintain a "Moderate Buy" rating with an average price target of $25.17. Insider trading activity included sales by the CEO and CFO, while institutional investors significantly increased their holdings, collectively owning 96.98% of the stock.
Relay Therapeutics (RLAY) Stock Faces Cash Burn Pressure Despite Flat Reaction
Relay Therapeutics (RLAY) saw its stock tick up slightly after Q2 2026 earnings, but the company continues to face significant cash burn pressure with a net loss of US$83.7 million and minimal revenue. Despite a recent US$300 million equity raise providing a strong cash position and narrowing trailing 12-month losses, the biotech firm remains dependent on external financing and future trial success. Investors are reportedly awaiting pipeline data more than reacting to current income statements.
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Relay Therapeutics announced its second-quarter 2026 financial results and corporate updates, highlighting progress in its zovegalisib program for breast cancer and vascular anomalies. The company selected a triplet regimen for first-line breast cancer, with a Phase 3 trial expected in early 2027, and presented positive initial data from its ReInspire trial in vascular anomalies. Relay Therapeutics reported approximately $911 million in cash, cash equivalents, and investments, projecting a cash runway into 2029.
FMR LLC (RLAY) discloses 21.27M-share, 10% holding in Relay Therapeutics
FMR LLC has filed an amended Schedule 13G, disclosing a significant 10.0% ownership stake in Relay Therapeutics, Inc. (RLAY), totaling 21,270,751.24 shares of common stock as of July 31, 2026. The filing indicates FMR LLC holds sole voting power over 21,153,779 shares and sole dispositive power over all 21.27 million shares, with Abigail P. Johnson also reporting sole dispositive power over the same amount. This disclosure highlights a substantial passive investment in the biotechnology company.
Relay Therapeutics, Inc. Stock 12‑Month Price Target Raised to $26.31, Implies 33% Upside
The average 12-month price target for Relay Therapeutics, Inc. (RLAY) stock has increased to $26.31 from $26.08, based on estimates from 13 analysts. This new target suggests a potential upside of approximately 33% from its Aug. 6 closing price. The consensus rating from 14 analysts remains a "Buy."
Relay Therapeutics Q2 Results: Sales drop 48% YoY, miss estimates
Relay Therapeutics reported a significant miss on its Q2 analyst estimates, with EPS of $(0.41) against an expected $(0.39). Sales plummeted 48.30% year-over-year to $350,000, falling short of the $872,727 estimate by nearly 60%. This performance indicates considerable top-line pressure and highlights operational challenges, despite the loss per share remaining unchanged from the previous year.
Earnings Flash (RLAY) Relay Therapeutics Posts Q2 Loss $0.41 per Share, vs. FactSet Est of $0.39 Loss
Relay Therapeutics (RLAY) reported a Q2 loss of $0.41 per share, which is higher than FactSet's estimated loss of $0.39 per share. The company also announced Q2 revenue of $400,000. Relay Therapeutics is a clinical-stage precision medicine company focused on developing therapies for cancer and genetic diseases.
Relay Therapeutics Q2 2026 earnings: Clinical spending rises with cash runway into 2029
Relay Therapeutics reported Q2 2026 revenue of $0.4 million, a decrease from the previous year, with a net loss of $83.7 million due to increased spending on clinical trials. Despite the wider loss, a May equity offering boosted cash reserves to $910.9 million, providing an expected
Earnings Flash (RLAY) Relay Therapeutics, Inc. Reports Q2 Revenue $400,000
Relay Therapeutics, Inc. (RLAY) announced its Q2 revenue of $400,000. This news follows another report indicating the company posted a Q2 loss of $0.41 per share, which was higher than FactSet's estimate of a $0.39 loss. The company is a clinical-stage precision medicine firm focused on developing therapies for cancer and genetic diseases.
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
Relay Therapeutics, Inc. (RLAY) reported a Q2 loss of $0.41 per share, meeting the Zacks Consensus Estimate but missing revenue estimates significantly at $0.35 million. Despite underperforming revenue expectations over the last four quarters, the stock has seen a 132.7% increase year-to-date, contrasting with the S&P 500's 12.8% gain. The company holds a Zacks Rank #3 (Hold), indicating it's expected to perform in line with the market in the near future.
Relay Therapeutics Inc (RLAY) News, Articles, Events & Latest Updates
This article compiles recent news and updates for Relay Therapeutics Inc (RLAY), including its Q2 2026 earnings report showing a loss and missed revenue estimates. Other news highlights include an insider stock sale topping $3 million, an AI biotech reporting significant revenue jump, and discussions around Relay Therapeutics' stock performance and a recent $175 million offering.
FMR LLC and Abigail Johnson disclose 9.4% Relay Therapeutics (RLAY) ownership in 13G
FMR LLC and Abigail Johnson have disclosed a 9.4% beneficial ownership in Relay Therapeutics (RLAY) through a Schedule 13G filing. This represents 20,015,113.24 shares of common stock as of June 30, 2026. FMR LLC holds sole voting power over 19,967,458 shares and sole dispositive power over all beneficially owned shares, with Abigail P. Johnson also having sole dispositive power over the same amount.
Dimensional Fund Advisors LP Buys 460,186 Shares of Relay Therapeutics, Inc. $RLAY
Dimensional Fund Advisors LP increased its stake in Relay Therapeutics, Inc. (RLAY) by 18.6%, acquiring an additional 460,186 shares and now owning 1.54% of the company. This comes as Relay Therapeutics reported weaker-than-expected quarterly results, yet analysts maintain a "Moderate Buy" consensus rating with a price target above the current stock price. Despite institutional buying, company insiders have sold a significant number of shares recently.
RLAY (RLAY) insider schedules 42,225-share sale after recent stock disposals
Relay Therapeutics (RLAY) insider Sekar Kathiresan has filed to sell 42,225 shares of common stock on August 4, 2026, with an estimated value of $826,465.70, in connection with a stock option exercise. This planned sale follows several recent disposals by Kathiresan in July 2026, totaling 126,055 shares for over $2.4 million. The transaction will be executed through Morgan Stanley Smith Barney LLC on NASDAQ.
J.P. Morgan Maintains Relay Therapeutics(RLAY.US) With Buy Rating
J.P. Morgan has reiterated its Buy rating for Relay Therapeutics (RLAY.US). This indicates a continued positive outlook from the investment bank regarding the company's stock.
RLAY (RLAY) filer Sekar Kathiresan plans 30,000-share sale after option exercise
Sekar Kathiresan, a reporting person for Relay Therapeutics (RLAY), has filed to sell 30,000 shares of common stock around July 31, 2026, for an indicated value of $563,553. This planned transaction is linked to a stock option exercise. The filing also reports two recent sales by Kathiresan in July 2026, totaling 96,055 shares.
Is Relay Therapeutics (RLAY) Turning Zovegalisib Updates Into a Credibility Test for Its Pipeline Strategy?
Relay Therapeutics is nearing its Q2 2026 earnings report, with significant investor attention on updates for its lead asset, zovegalisib, and other pipeline programs. Analysts are increasingly optimistic, anticipating strong earnings and progress in oncology and genetic disease trials. The company recently completed a US$175 million equity raise, highlighting its continued need for funding despite an unprofitable model, and some valuation reports suggest its shares may be trading at a premium.
Relay Therapeutics to report Q2 2026 results on Aug 6
Relay Therapeutics, Inc. (NASDAQ: RLAY) will announce its second-quarter 2026 financial results and corporate highlights after U.S. financial markets close on August 6, 2026. The clinical-stage precision medicine company focuses on developing therapies for cancer and genetic diseases, with its lead asset, zovegalisib, currently in a Phase 3 trial for metastatic breast cancer and under investigation for PI3Kα-driven vascular anomalies. Investors will be keen to assess the company's financial health, cash runway, burn rate, and pipeline progress.
Relay Therapeutics (RLAY) CFO sells 1,459 shares to cover taxes
Relay Therapeutics' CFO, Thomas Catinazzo, sold 1,459 shares of common stock at $18.61 per share on July 28, 2026. This transaction was solely to cover income tax withholding obligations from the vesting of 3,269 Restricted Stock Units (RSUs) and was conducted without his discretion, adhering to company policies. Following the sale, Catinazzo beneficially owns 158,285 shares, including 6,538 shares underlying RSUs.
Relay Therapeutics to report Q2 results after markets close
Relay Therapeutics is scheduled to release its second-quarter 2026 financial results and provide a corporate update on August 6, 2026, after the U.S. market closes. This information was originally published by Relay Therapeutics Inc. via GlobeNewswire. The news brief was generated by Public Technologies (PUBT) using AI and is for informational purposes only.
Relay Therapeutics (RLAY) officer has 748 shares sold to satisfy RSU tax
Relay Therapeutics' Chief Corporate Development Officer, Peter Rahmer, sold 748 shares of common stock at $18.61 per share on July 28, 2026. This sale was non-discretionary and executed to cover income tax withholding obligations from the vesting of 3,051 Restricted Stock Units (RSUs). After the transaction, Rahmer holds 228,165 shares, including 6,102 shares underlying RSUs.
